Complement activation is common in patients with systemic lupus erythematosus (SLE), resulting in hypocomplementemia and deposition of complement at sites of tissue damage. The availability of mice ...
Achillion Pharmaceuticals, Inc. ACHN announced that it has started a phase I study on its first orally administered small molecule complement factor D inhibitor, ACH-4471. The randomized, ...
Complement potentiates various forms of cancer therapy, including antibody-mediated cytotoxicity, vaccines and radiotherapy. Complement-dependent cytotoxicity can be improved by optimizing antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback